echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > ProQR and Eli Lilly expand RNA editing collaboration, shares jump 63%

    ProQR and Eli Lilly expand RNA editing collaboration, shares jump 63%

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On December 22, Eli Lilly and Company partnered with ProQR Therapeutics jointly announced the expansion of its licensing and collaboration agreement to expand collaboration on RNA editing technologies with a focus on the discovery, development and commercialization
    of new gene drugs.

    Affected by this news, ProQR Therapeutics' share price jumped 63.
    64% on the day, and now has a total market value of $193 million

    Up 63.

    Under the terms of this expanded agreement, Eli Lilly will use ProQR's Axiomer® RNA Edit the platform to obtain other targets
    of the central nervous system and peripheral nervous system.
    Eli Lilly will make an upfront payment of $75 million and equity investments, as well as an option to further expand the partnership for a consideration of $50 million
    In addition, Eli Lilly has the option to provide ProQR with access to the company's proprietary delivery technology that can be used in its wholly-owned pipeline

    Other targets under the terms of this expanded agreement
    $75 million, $50 million

    Under its original and expanded agreements, ProQR is eligible for research, development and commercialization milestones of up to approximately $3.
    75 billion, as well as tiered royalties
    of up to mid-single-digit product sales.

    Approximately $3.
    75 billion

    Original English text: _mstmutation="1" _msthash="220730" _msttexthash="10499125">

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.